Literature DB >> 34799745

Transoral incisionless fundoplication with Medigus ultrasonic surgical endostapler (MUSE) for the treatment of gastro-esophageal reflux disease: outcomes up to 3 years.

Sabrina Gloria Giulia Testoni1, Maria Bernadette Cilona1, Giorgia Mazzoleni2, Lorella Fanti1, Emanuela Ribichini1, Giulia Martina Cavestro1, Dario Esposito1, Edi Viale1, Chiara Notaristefano1, Raffaella Alessia Zuppardo1, Francesco Azzolini1, Sandro Passaretti1, Pier Alberto Testoni3.   

Abstract

BACKGROUND: Transoral incisionless fundoplication (TIF) with Medigus Ultrasonic Surgical Endostapler (MUSE) is a new intervention for treatment of gastro-esophageal reflux disease (GERD). We aimed at assessing the clinical, functional, and endoscopic effects of TIF by MUSE.
METHODS: Forty-six patients underwent TIF. Proton pump inhibitor (PPI) consumption, GERD-health-related quality of life (HRQL) and reflux symptom index (RSI) questionnaires, upper gastrointestinal (GI) endoscopy, esophageal 24-h pH-impedance recording, and high-resolution manometry (HRM) were done before TIF and scheduled 6 and 12 months later (HRM only at 6-month). PPI consumption and symptoms were then assessed yearly. Data up to 3 years are reported in this study (PP- and ITT-analysis).
RESULTS: TIF was successfully performed in 45/46 patients; in one patient esophageal intubation was impossible. Perforation occurred in two cases. One patient required surgery within 6 months. Clinical follow-up was available for 42 patients at 6 months and 1 year, 35 patients at 2 years, and 31 patients at 3 years. At 1, 2, and 3 years, PPI consumption was stopped, respectively, in 64.3%, 62.9%, and 74.2% of cases (ITT-analysis: 58.7%, 56.4%, and 65.7%). GERD-HRQL and RSI scores decreased at least 50%, respectively, in 71.5% and 76.2%, 71.4% and 68.6%, and 67.7% of cases (ITT-analysis: 65.2% and 69.6%, 64.1% and 61.5%, and 60%). A significant improvement of both scores was observed up to 3 years. 6-month and 1-year functional follow-up were possible in 31 and 20 patients. HRM showed significant increase of the median lower esophageal sphincter length and rate of peristaltic waves. Esophageal pH-impedance recording found significantly fewer acid, proximal and total refluxes, and percentage of esophageal pH < 4 total time at 6 months, but not at 1 year.
CONCLUSION: TIF by MUSE significantly improved symptoms and PPIs consumption up to 3 years. However, esophagitis still persisted in one-third of cases at 1 year and functional improvement at 6 months was not confirmed at 1 year. Severe complications requiring surgery occurred in two cases. CLINICALTRIALS: GOV: ID: NCT03669874.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gastro-esophageal reflux disease; Medigus Ultrasonic Surgical Endostapler (MUSE); Transoral incisionless fundoplication

Mesh:

Substances:

Year:  2021        PMID: 34799745     DOI: 10.1007/s00464-021-08860-w

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  19 in total

Review 1.  Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis.

Authors:  Xiaoquan Huang; Shiyao Chen; Hetong Zhao; Xiaoqing Zeng; Jingjing Lian; Yujen Tseng; Jie Chen
Journal:  Surg Endosc       Date:  2016-08-05       Impact factor: 4.584

2.  Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis.

Authors:  Thomas R McCarty; Michael Itidiare; Basile Njei; Tarun Rustagi
Journal:  Endoscopy       Date:  2018-04-06       Impact factor: 10.093

3.  Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.

Authors:  Gerasimos Stefanidis; Nikos Viazis; Nikolaos Kotsikoros; Nikolaos Tsoukalas; Eythymia Lala; Loukas Theocharis; Andreas Fassaris; Spilios Manolakopoulos
Journal:  Dis Esophagus       Date:  2017-02-01       Impact factor: 3.429

4.  Three-year results of a multicenter prospective study of transoral incisionless fundoplication.

Authors:  Vinciane Muls; Alexander J Eckardt; Michele Marchese; Boris Bastens; Michel Buset; Jacques Devière; Hubert Louis; Amin Rajan; Michael A Daniel; Guido Costamagna
Journal:  Surg Innov       Date:  2012-09-11       Impact factor: 2.058

5.  Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice.

Authors:  Bart P L Witteman; Rob Strijkers; Eva de Vries; Liza Toemen; José M Conchillo; Wim Hameeteman; Pieter C Dagnelie; Ger H Koek; Nicole D Bouvy
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

6.  Trans-oral anterior fundoplication: 5-year follow-up of pilot study.

Authors:  Aviel Roy-Shapira; Amol Bapaye; Suhas Date; Rajendra Pujari; Shivangi Dorwat
Journal:  Surg Endosc       Date:  2015-03-18       Impact factor: 4.584

7.  The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.

Authors:  Karim S Trad; William E Barnes; Elizabeth R Prevou; Gilbert Simoni; Jennifer A Steffen; Ahmad B Shughoury; Mamoon Raza; Jeffrey A Heise; Mark A Fox; Peter G Mavrelis
Journal:  Surg Innov       Date:  2018-02-06       Impact factor: 2.058

8.  Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study.

Authors:  Munyaradzi Chimukangara; Anahita D Jalilvand; W Scott Melvin; Kyle A Perry
Journal:  Surg Endosc       Date:  2018-08-27       Impact factor: 4.584

9.  Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device.

Authors:  Hong Joo Kim; Chang-Il Kwon; William R Kessler; Don J Selzer; Gail McNulty; Amol Bapaye; Luigi Bonavina; Glen A Lehman
Journal:  Surg Endosc       Date:  2015-11-04       Impact factor: 4.584

10.  Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years.

Authors:  Pier Alberto Testoni; Sabrina Testoni; Giovanni Distefano; Giorgia Mazzoleni; Lorella Fanti; Sandro Passaretti
Journal:  Endosc Int Open       Date:  2019-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.